Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin.
The two companies partnered to incorporate and integrate connected insulin delivery devices, continuous glucose monitors and electronic health records. Novo Nordisk also intends to make an equity investment in Amalgam, according to a news release.
“We’re expanding Dose Check’s geographic footprint and simplifying the way people living with diabetes and HCPs access digital health solutions,” said Thomas Thestrup-Terp, Novo Nordisk VP, digital strategy & solutions. We are now investing further in our partnership with Amalgam with the ambition to use innovative digital health solutions to further improve personalized care for people living with diabetes.”
The expanded partnership aims to bolster the existing agreement and product suite between Amalgam Rx and Novo Nordisk.
Amalgam Rx’s platform helps alleviate the stresses of starting insulin therapy. The company said those with type 2 diabetes often feel anxiety and confusion. Additionally, healthcare providers can also find it challenging and time-consuming to decipher incomplete and inaccurate self-management data.
Dose Check allows physicians to choose from clinically-validated basal insulin algorithms and tailor them to patients’ needs. Patients record their blood glucose levels and the app can suggest an increase in insulin based on their doctor’s recommendation.
“It’s incredibly rewarding and validating to see the continued expansion of Dose Check,” said Amalgam Rx CEO Ryan Sysko. “We are very proud of the program’s progress to date and of our collaboration with Novo Nordisk.”
